CBG: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Cannabigerol (CBG) |FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition) |used_for=Investigational use in cancer research for potential anti-tumor effects |clinical_trial_phase=Preclinical studies and early research |common_side_effects=Not specifically documented; cannabinoids are generally considered to have a favorable safety profile, but specific studies on CBG's side effects are limited |O...") |
No edit summary |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{TreatmentInfo | {{TreatmentInfo | ||
|drug_name= | |drug_name=Sativex (Nabiximols) | ||
|FDA_approval= | |FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis | ||
|used_for=Investigational use in | |used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management | ||
|clinical_trial_phase= | |clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma | ||
|common_side_effects= | |common_side_effects=Fatigue, dizziness, nausea, mouth irritation | ||
|OS_with= | |OS_with=The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone | ||
|PFS_with= | |PFS_with=Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival | ||
|usefulness_rating= | |usefulness_rating=4 | ||
|notes= | |notes=In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma. | ||
| | |treatment_category=Investigational Drugs | ||
|links= | |links= | ||
}} | |toxicity_level=2 | ||
|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country. | |||
|overview=Sativex (Nabiximols) is an investigational drug not approved by the FDA in the United States but used in several countries to manage spasticity in multiple sclerosis and is being studied for its potential benefits in glioblastoma treatment. A 2021 Phase 2 clinical trial showed promising results, indicating an increase in overall survival when Sativex was used alongside temozolomide, although more research is needed to fully understand its effects and safety.}} | |||
Latest revision as of 01:19, 18 January 2025
| Property | Information |
|---|---|
| Drug Name | Sativex (Nabiximols) |
| Overview | Sativex (Nabiximols) is an investigational drug not approved by the FDA in the United States but used in several countries to manage spasticity in multiple sclerosis and is being studied for its potential benefits in glioblastoma treatment. A 2021 Phase 2 clinical trial showed promising results, indicating an increase in overall survival when Sativex was used alongside temozolomide, although more research is needed to fully understand its effects and safety. |
| FDA Approval | Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis |
| Used for | Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management |
| Clinical Trial Phase | Phase 2 clinical trial in 2021 indicated for glioblastoma |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Fatigue, dizziness, nausea, mouth irritation |
| OS without | Not specified |
| OS with | The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone |
| PFS without | Not specified |
| PFS with | Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country. |
Notes: In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.
From Ben Williams Book: Not specified
Loading comments...
